Novartis Bone Drug Action Doomed By Statute Of Limitations

Law360, New York (March 16, 2012, 9:04 PM EDT) -- A New Jersey state judge on Friday dismissed a product liability suit against Novartis Pharmaceuticals Corp. over its bone drug Zometa, citing a recent Virginia Supreme Court decision affirming that claims in a similar suit are barred by the state's statute of limitations.

In the New Jersey suit, Virginia resident Charles Irby claimed Zometa caused him to develop osteonecrosis — also known as “bone death” — of the jaw, and he sought punitive damages from Novartis. He was diagnosed with the condition in December 2003 and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.